Premium
P1–222: Plasma markers and cognitive decline in the ADAPT clinical trial
Author(s) -
Leoutsakos JeannieMarie,
Han Dingfen,
Tighe Sarah,
Lyketsos Constantine
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.446
Subject(s) - creatinine , uric acid , bilirubin , medicine , dementia , cholesterol , cognitive decline , linear regression , gastroenterology , statistics , mathematics , disease
13.0 0 16 15 31 SLAAC 13.0 and 1 ApoE4 33 (37) 60 (44-74) 86 (73-95) 82 (65-93) 68 (54-80) 1 6 22 28 2 0 5 5 Total 22 42 64 11.0 0 15 14 29 11.0 and 1 28 (31) 49 (34-64) 86 (73-95) 79 (59-92) 62 (49-74) 1 6 17 23 2 0 5 5 Total 21 36 57 9.0 0 12 11 23 9.0 and 1 26 (29) 49 (34-64) 91 (78-98) 85 (65-96) 64 (50-75) 1 4 17 21 2 0 5 5 Total 16 33 49 7.0 0 7 10 17 7.0 and 1 20 (22) 42 (28-58) 98 (88-100) 95 (75-100) 62 (50-74) 1 1 14 15 2 0 5 5 Total 8 29 37 5.0 0 5 7 12 5.0 and 1 13 (15) 29 (16-44) 100 (88-100) 100 (66-100) 58 (46-69) 1 0 8 8 2 0 5 5 Total 5 20 25 3.0 0 3 5 8 3.0 and 1 7 (8) 16 (7-30) 100 (88-100) 100 (47-100) 54 (42-65) 1 0 3 3 2 0 4 4 Total 3 12 15